Compare Stocks: MCRB, ORGO, DTIL, and NBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.50 -5.2%	$7.78	$3.53 ▼ $9.62	$179.28M	1.24	318,209 shs	233,799 shs
MCRB Seres Therapeutics	$4.59 -3.0%	$5.18	$4.32 ▼ $29.98	$46.13M	0.21	69,874 shs	26,934 shs
NBP I-Mab	$1.59 -1.6%	$1.80	$1.46 ▼ $6.79	$184.46M	1.5	703,193 shs	211,660 shs
ORGO Organogenesis	$1.48 -1.7%	$2.06	$1.45 ▼ $7.08	$189.80M	1.29	1.03 million shs	270,003 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	-4.32%	-8.17%	-7.67%	+8.72%	+48.81%
MCRB Seres Therapeutics	-5.59%	-17.31%	+4.19%	-20.77%	-70.27%
NBP I-Mab	+1.26%	-10.56%	-17.86%	+6.62%	+160,999,900.00%
ORGO Organogenesis	+0.67%	-12.28%	-16.20%	-37.50%	-69.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$6.50 -5.2%	$7.78	$3.53 ▼ $9.62	$179.28M	1.24	318,209 shs	233,799 shs
MCRB Seres Therapeutics	$4.59 -3.0%	$5.18	$4.32 ▼ $29.98	$46.13M	0.21	69,874 shs	26,934 shs
NBP I-Mab	$1.59 -1.6%	$1.80	$1.46 ▼ $6.79	$184.46M	1.5	703,193 shs	211,660 shs
ORGO Organogenesis	$1.48 -1.7%	$2.06	$1.45 ▼ $7.08	$189.80M	1.29	1.03 million shs	270,003 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	-4.32%	-8.17%	-7.67%	+8.72%	+48.81%
MCRB Seres Therapeutics	-5.59%	-17.31%	+4.19%	-20.77%	-70.27%
NBP I-Mab	+1.26%	-10.56%	-17.86%	+6.62%	+160,999,900.00%
ORGO Organogenesis	+0.67%	-12.28%	-16.20%	-37.50%	-69.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	388.19% Upside
MCRB Seres Therapeutics	2.25	Hold	$17.00	264.03% Upside
NBP I-Mab	2.00	Hold	$9.00	460.75% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	192.00% Upside

Current Analyst Ratings Breakdown

Latest MCRB, ORGO, DTIL, and NBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	NBP I-Mab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/20/2026	NBP I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/11/2026	MCRB Seres Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$45.06M	4.05	N/A	N/A	$4.03 per share	1.64
MCRB Seres Therapeutics	$790K	59.41	$1.01 per share	4.61	$4.89 per share	0.96
NBP I-Mab	N/A	N/A	N/A	N/A	$2.00 per share	N/A
ORGO Organogenesis	$564.17M	0.34	$0.65 per share	2.30	$2.36 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
MCRB Seres Therapeutics	$5.70M	-$2.43	N/A	N/A	N/A	-1,192.94%	-114.82%	-34.15%	11/4/2026 (Estimated)
NBP I-Mab	-$46.27M	-$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)

Latest MCRB, ORGO, DTIL, and NBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	NBP I-Mab	N/A	-$0.1610	N/A	-$0.1610	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
8/5/2026	Q2 2026	MCRB Seres Therapeutics	-$2.18	$0.47	+$2.65	$0.47	$0.18 million	$0.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.50	12.82	12.82
MCRB Seres Therapeutics	N/A	2.11	2.11
NBP I-Mab	N/A	7.64	8.09
ORGO Organogenesis	0.07	3.52	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
MCRB Seres Therapeutics	59.34%
NBP I-Mab	38.38%
ORGO Organogenesis	49.57%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
MCRB Seres Therapeutics	5.20%
NBP I-Mab	22.10%
ORGO Organogenesis	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
MCRB Seres Therapeutics	330	10.05 million	9.52 million	Optionable
NBP I-Mab	30	115.65 million	90.09 million	N/A
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable

MCRB, ORGO, DTIL, and NBP Headlines

Recent News About These Companies

BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO

September 4, 2026 | marketbeat.com

Organogenesis stock trades without a fresh catalyst, recent results define the picture

August 29, 2026 | ad-hoc-news.deA

Deutsche Bank AG Purchases New Shares in Organogenesis $ORGO

August 26, 2026 | marketbeat.com

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Organogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annually

August 8, 2026 | seekingalpha.com

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Organogenesis Launches New $75 Million At-The-Market Offering

August 6, 2026 | tipranks.com

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

August 6, 2026 | globenewswire.com

Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers

July 27, 2026 | quiverquant.comQ

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

July 27, 2026 | globenewswire.com

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

July 9, 2026 | globenewswire.com

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

July 6, 2026 | globenewswire.com

Organogenesis Stockholders Reelect Board and Approve Governance Items

June 16, 2026 | tipranks.com

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

June 15, 2026 | seekingalpha.com

Organogenesis Earnings Call: Deep Pain, Long Road

June 7, 2026 | theglobeandmail.com

Truist Securities initiates coverage of Organogenesis Holdings (ORGO) with hold recommendation

May 29, 2026 | msn.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 22, 2026 | finance.yahoo.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 20, 2026 | insidermonkey.com

Organogenesis (ORGO) Q1 2026 Earnings Transcript

May 8, 2026 | fool.com

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MCRB, ORGO, DTIL, and NBP Company Descriptions

Precision BioSciences NASDAQ:DTIL

$6.50 -0.36 (-5.19%)

As of 03:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Seres Therapeutics NASDAQ:MCRB

$4.59 -0.14 (-2.96%)

As of 03:30 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

I-Mab NASDAQ:NBP

$1.58 -0.03 (-1.55%)

As of 03:29 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Organogenesis NASDAQ:ORGO

$1.48 -0.03 (-1.67%)

As of 03:29 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, ORGO, DTIL, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, ORGO, DTIL, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, ORGO, DTIL, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MCRB, ORGO, DTIL, and NBP Company Descriptions

Precision BioSciences NASDAQ:DTIL

Seres Therapeutics NASDAQ:MCRB

I-Mab NASDAQ:NBP

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MCRB, ORGO, DTIL, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MCRB, ORGO, DTIL, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MCRB, ORGO, DTIL, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MCRB, ORGO, DTIL, and NBP Company Descriptions

Precision BioSciences NASDAQ:DTIL

Seres Therapeutics NASDAQ:MCRB

I-Mab NASDAQ:NBP

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools